Shares of Altimmune (NASDAQ: ALT), a clinical-stage biopharmaceutical company, are on the move following a positive clinical readout. Investors excited about the company's potential new weight loss drug drove the stock 23% higher as of 12:34 p.m. on Wednesday. Altimmune's weight loss drug candidate, ALT-801, is a GLP-1 receptor agonist that also activates glucagon receptors.
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 14 June 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginnin
The Zacks Analyst Blog Highlights: Microsoft, Nike, Novo Nordisk, Caterpillar and General Electric